Metacrine, Inc. was a San Diego, California clinical-stage biopharmaceutical company founded in 2014 to develop differentiated therapies for liver and gastrointestinal disease. It built a proprietary farnesoid X receptor (FXR) platform on a distinct chemical scaffold and advanced two oral, once-daily FXR agonists — MET409 and MET642 — through Phase 1 and Phase 2 trials in non-alcoholic steatohepatitis (NASH), alongside exploratory work in inflammatory bowel disease. Backed by ARCH Venture Partners, Polaris Partners, venBio and EcoR1 Capital, it raised a $36M round in 2015 and a $65M Series C in June 2018 before pricing an initial public offering on 2020-09-15 of 6,540,000 shares at $13.00, for roughly $85.0M gross, and listing on the Nasdaq Capital Market as MTCR. Equillium, Inc. agreed to acquire the company in an all-stock transaction announced 2022-09-06, but the two mutually terminated the merger agreement on 2022-12-23. The board approved a Plan of Dissolution on 2023-01-24; Nasdaq issued a minimum-bid-price delisting notice on 2023-01-31, trading was suspended on 2023-02-09 and delisting took effect 2023-03-13; the FXR program assets were sold under a February 2023 term sheet for up to $4.0M in cash plus assumed liabilities; stockholders approved the dissolution on 2023-03-23; and the company filed a Certificate of Dissolution with the Delaware Secretary of State on 2023-03-24, effective on filing under DGCL Section 275. Metacrine was a drug developer, not a software vendor, and it never published a developer program, public API, SDK, webhook surface, or machine-readable specification of any kind. Its domain metacrine.com has since lapsed and is parked. This profile is retained as a historical record; there is no API surface to enrich.
Metacrine is profiled on the APIs.io network. Tagged areas include Company, Defunct, Biotechnology, Pharmaceuticals, and Life Sciences.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/metacrine: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: metacrine
name: Metacrine
description: Metacrine, Inc. was a San Diego, California clinical-stage biopharmaceutical company founded in 2014 to develop
differentiated therapies for liver and gastrointestinal disease. It built a proprietary farnesoid X receptor (FXR) platform
on a distinct chemical scaffold and advanced two oral, once-daily FXR agonists — MET409 and MET642 — through Phase 1 and
Phase 2 trials in non-alcoholic steatohepatitis (NASH), alongside exploratory work in inflammatory bowel disease. Backed
by ARCH Venture Partners, Polaris Partners, venBio and EcoR1 Capital, it raised a $36M round in 2015 and a $65M Series C
in June 2018 before pricing an initial public offering on 2020-09-15 of 6,540,000 shares at $13.00, for roughly $85.0M gross,
and listing on the Nasdaq Capital Market as MTCR. Equillium, Inc. agreed to acquire the company in an all-stock transaction
announced 2022-09-06, but the two mutually terminated the merger agreement on 2022-12-23. The board approved a Plan of Dissolution
on 2023-01-24; Nasdaq issued a minimum-bid-price delisting notice on 2023-01-31, trading was suspended on 2023-02-09 and
delisting took effect 2023-03-13; the FXR program assets were sold under a February 2023 term sheet for up to $4.0M in cash
plus assumed liabilities; stockholders approved the dissolution on 2023-03-23; and the company filed a Certificate of Dissolution
with the Delaware Secretary of State on 2023-03-24, effective on filing under DGCL Section 275. Metacrine was a drug developer,
not a software vendor, and it never published a developer program, public API, SDK, webhook surface, or machine-readable
specification of any kind. Its domain metacrine.com has since lapsed and is parked. This profile is retained as a historical
record; there is no API surface to enrich.
url: https://raw.githubusercontent.com/api-evangelist/metacrine/refs/heads/main/apis.yml
x-api-posture: no-product-api
x-api-posture-basis: observed
x-api-posture-note: Metacrine was a drug developer, not a software vendor, and it never published a developer program, public
API, SDK, webhook surface, or machine-readable specification of any kind.
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: defunct-no-api-surface
x-status: defunct
x-founded: '2014'
x-headquarters: San Diego, California, United States
x-ticker: 'NASDAQ: MTCR (delisted 2023-03-13)'
x-shutdown-date: '2023-03-24'
x-shutdown-note: Stockholders approved a Plan of Dissolution on 2023-03-23 and the company filed a Certificate of Dissolution
with the Delaware Secretary of State on 2023-03-24, effective upon filing under DGCL Section 275. Under DGCL Section 278
the corporate existence continues at least three years solely to wind up affairs. Confirmed from the company's own Form
8-K (SEC CIK 0001634379).
x-domain-status: expired-parked
x-domain-note: metacrine.com was registered 2014-11-11 through Network Solutions — the company's own original registration
— but has lapsed and is now delegated to NS1/NS2.PENDINGRENEWALDELETION.COM and wildcarded to the Media.net/Confluence Networks
parking address 208.91.197.132. Every subdomain (www, api, docs, developer, developers, app, investors) resolves to that
same address, TLS on 443 resets before a handshake, and every path returns HTTP 200 with a 122- or 195-byte "Error. Page
cannot be displayed" stub — including a control path that cannot exist. Those 200s are not documents. See well-known/metacrine-well-known.yml.
metacrine.com is NOT wired as a Website pointer.
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
specificationVersion: '0.23'
created: '2026-08-25'
modified: '2026-08-25'
tags:
- Company
- Defunct
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Drug Discovery
- Therapeutics
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: SecondaryMarket
url: https://forgeglobal.com/metacrine_stock/
- type: WellKnownProbe
url: well-known/metacrine-well-known.yml
x-coverage:
state: none
reason: defunct
detail: Metacrine, Inc. was a clinical-stage biopharmaceutical developer that never shipped software, and it filed a Certificate
of Dissolution with the Delaware Secretary of State on 2023-03-24; its original domain metacrine.com has since lapsed
onto Network Solutions' PENDINGRENEWALDELETION nameservers and a Media.net parking wildcard that answers HTTP 200 with
the same 122-byte "Error. Page cannot be displayed" stub for every path and every subdomain, including a control path
that cannot exist, so none of those 200s is a document.
evidence:
- url: https://www.sec.gov/Archives/edgar/data/1634379/000119312523079293/d453945d8k.htm
status: 200
- url: http://metacrine.com/
status: 200
- url: http://metacrine.com/openapi.json
status: 200
- url: http://metacrine.com/.well-known/agent-card.json
status: 200
- url: http://metacrine.com/control-path-does-not-exist-98765
status: 200
- url: https://metacrine.com/
status: 0
- url: https://api.github.com/orgs/metacrine
status: 404
- url: https://registry.npmjs.org/metacrine
status: 404
- url: https://forgeglobal.com/metacrine_stock/
status: 403
checked: '2026-08-25'
x-enrichment:
date: '2026-08-25'
status: minimal
artifacts_added: 1
pass: local-v1
Kin Score
How this is scored →